Maia Marina Valente, Cunha Maria da Graça Souza, Cunha Carolina Souza
Alfredo da Matta Foundation of Tropical Dermatology and Venereology, Manaus, AM, Brazil.
An Bras Dermatol. 2013 Mar-Apr;88(2):205-10. doi: 10.1590/S0365-05962013000200003.
After the introduction of the multidrug therapy, there was a decline in the coefficients of prevalence and detection of new cases of leprosy. However, the records of drug resistance and relapses are threatening factors in leprosy control. Hence, new alternative schemes and monitoring of adverse effects to avoid treatment abandonment are important considerations.
Describe the side effects of a multidrug regimen containing minocycline, ofloxacin, and clofazimine in multibacillary leprosy patients.
We conducted a prospective, descriptive, and observational study with multibacillary patients, including cases of intolerance to standard MDT and relapses. The study was carried out at Fundação Alfredo da Matta (Alfredo da Matta Foundation), in Manaus, Amazonas, from April 2010 to January 2012. The patients received alternative therapy, which consisted of daily self-administered doses of 100mg of minocycline, 400 mg of ofloxacin, and 50mg of clofazimine and a supervised monthly dose of 300mg of clofazimine for six months, followed by eighteen months of daily doses of ofloxacin 400mg, clofazimine 50mg, and a supervised monthly dose of clofazimine 300mg.
Twenty-one cases were included. Mild and transitory side effects occurred in 33.3% of patients. Of the total episodes, 45.9% were attributed to ofloxacin and they included abdominal pain, nausea, vomiting, headache, and insomnia; 21.6% were due to clofazimine, with 100% of patients presenting skin pigmentation. The mean time for the development of adverse effects after beginning the therapy was 15.2 days.
All patients tolerated the drugs well, and compliance was satisfactory, with no serious events. Unlike other standard MDT studies had shown, no treatment was stopped due to side effects. Nevertheless, patient follow-up and studies with bigger samples are necessary to guarantee the efficacy and safety of the alternative regimen as a second-line scheme in multi-drug therapy.
在采用多药联合疗法后,麻风病新发病例的患病率和检出率系数有所下降。然而,耐药性和复发记录是麻风病控制中的威胁因素。因此,新的替代方案以及对不良反应的监测以避免治疗中断是重要的考虑因素。
描述含米诺环素、氧氟沙星和氯法齐明的多药联合方案在多菌型麻风病患者中的副作用。
我们对多菌型患者进行了一项前瞻性、描述性和观察性研究,包括对标准多药联合疗法不耐受和复发的病例。该研究于2010年4月至2012年1月在亚马孙州马瑙斯的阿尔弗雷多·达·马塔基金会(Fundação Alfredo da Matta)进行。患者接受替代疗法,即每日自行服用100毫克米诺环素、400毫克氧氟沙星和50毫克氯法齐明,每月在监督下服用300毫克氯法齐明,持续6个月,随后18个月每日服用400毫克氧氟沙星、50毫克氯法齐明,每月在监督下服用300毫克氯法齐明。
纳入21例病例。33.3%的患者出现轻度和短暂性副作用。在所有不良反应事件中,45.9%归因于氧氟沙星,包括腹痛、恶心、呕吐、头痛和失眠;21.6%归因于氯法齐明,100%的患者出现皮肤色素沉着。开始治疗后出现不良反应的平均时间为15.2天。
所有患者对药物耐受性良好,依从性令人满意,未发生严重事件。与其他标准多药联合疗法研究结果不同,没有因副作用而停止治疗的情况。然而,需要对患者进行随访并开展更大样本量的研究,以确保替代方案作为多药联合疗法二线方案的有效性和安全性。